Rifampin Capsules USP — Class II drug recall D-0100-2023
Terminated recall by Lupin Pharmaceuticals Inc., reported 2023-01-18, distributed nationwide. Failed Impurities/Degradation Specifications: Failure observed in related substance testing during long term s
| Recall number | D-0100-2023 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Lupin Pharmaceuticals Inc., Baltimore, MD, United States |
| Recall initiated | 2022-12-12 |
| Classified | 2023-01-09 |
| Reported by FDA | 2023-01-18 |
| Terminated | 2024-01-31 |
| Distributed | Nationwide (US) |
| Quantity | 16,056 |
| Reason classes | specification failure |
| NDC | 68180-0658, 68180-0658-01, 68180-0658-06, 68180-0659, 68180-0659-01, 68180-0659-06, 68180-0659-07 |
| Lot numbers | A200171 |
| Expiration dates | 2023-12 |
Product
Rifampin Capsules USP, 300 mg, 30-count bottle; Rx Only, Manufactured for: Lupin Pharmaceuticals Baltimore, Maryland 21202, Manufactured by: Lupin Limited Aurangabad 431 210 India. NDC 68180-659-06
Reason for recall
Failed Impurities/Degradation Specifications: Failure observed in related substance testing during long term stability study.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0100-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.